CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 60 enrolled
Drug / intervention
Sense2Quit Appbehavioral
Likely dose
Sense2Quit app accessed via smartphone linked to smartwatchAI-extracted
Key inclusion· 8
  • ✓Confirmed PLWH (People Living with HIV) via medical records or ART medication bottles
  • ✓Age ≥18 years
  • ✓Owns an Android smartphone
  • ✓Able to read and understand English
Key exclusion· 7
  • ✕Use of tobacco products other than cigarettes (cigars, pipe tobacco, chew, snuff)
  • ✕Planning to move within 3 months of enrollment
  • ✕Medical condition that precludes nicotine patch use
  • ✕Current use of NRT or other smoking cessation medications (Chantix, Zyban)

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05609032
NCT05609032N/ACompleted
CompareCT.gov

Development and Pilot Testing of the Sense2Quit App

Columbia University·interventional·Posted Nov 8, 2022·Updated Nov 6, 2024

In Brief

A clinical study evaluating Sense2Quit App for Smoking Cessation and HIV Infections. Completed, enrolled 60 participants across 1 site.

Detailed Summary

This is a pilot randomized controlled trial to examine the feasibility, acceptability and preliminary efficacy of the Sense2Quit App in a sample of 60 PLWH who smoke.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking Cessation, HIV Infections
CountriesUnited States
CollaboratorsCase Western Reserve University, National Cancer Institute (NCI)

Timeline

N/ACompletedFinished
2023202420252026
First PostedNov 8, 2022
Enrollment StartMar 6, 2023
Primary CompletionJan 12, 2024
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 3.6 years ago

Interventions

Sense2Quit Appbehavioral

Participants in the intervention arm will receive access to Sense2Quit, a smartphone app that links to a smartwatch.